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Abstract  1 
Background: Catheter ablation is an effective therapy for ventricular 2 
fibrillation (VF) arising from the Purkinje system in ischemic heart disease. 3 
However, some patients experience newly emergent monomorphic 4 
ventricular tachycardia (VT) after the ablation of VF. We evaluated the 5 
prevalence and mechanism of monomorphic VT after VF ablation. 6 
Methods and Results: Twenty-one consecutive patients with primary VF 7 
due to ischemic heart disease who underwent catheter ablation were 8 
retrospectively analyzed. Twenty of 21 patients were in electrical storm. 9 
Ventricular premature contractions triggering VF arose from the left 10 
Purkinje system and were targeted for ablation. Before the ablation, 14 of 21 11 
patients had only VF, and the other 7 had VF and concomitant monomorphic 12 
VT. Four of the 14 patients with only VF (29%) exhibited newly emergent 13 
monomorphic VT after VF ablation. Three of these patients had 14 
Purkinje-related VTs, which were successfully eliminated by ablation of a 15 
Purkinje network located in the same low-voltage area as the site of prior 16 
successful VF ablation. During a median follow-up of 28 months 17 
(interquartile range: 16–68 months), VF recurred in 6 of 21 patients (29%); 18 
however, there were no electrical storms or monomorphic VT, and all 19 
recurring arrhythmias were controlled by medical therapy alone.  20 
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Conclusions: Over a fifth of patients with primary ischemic VF experienced 1 
newly emergent Purkinje-related monomorphic VT after VF ablation. The 2 
circuit of the monomorphic VT associated with the Purkinje network was 3 
located in the same low-voltage area as the Purkinje tissue that triggered VF, 4 
and could be suppressed by additional ablation. 5 
 6 
Key Words: ablation, ischemic heart disease, Purkinje network, ventricular 7 
fibrillation, ventricular tachycardia 8 
 9 
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Introduction 1 
 Ventricular fibrillation (VF) is a life-threatening arrhythmia that 2 
often occurs in patients with ischemic heart disease (IHD). The Purkinje 3 
system has been reported to play a pivotal role in triggering and perpetuating 4 
VF,1 and catheter ablation targeting Purkinje potentials can suppress this 5 
arrhythmia.2-9 Catheter ablation is an effective therapy and appears to have a 6 
high success rate for the treatment of VF associated with Purkinje system in 7 
general. However, some patients experience newly emergent monomorphic 8 
ventricular tachycardia (VT) after VF ablation.  9 
The mechanism of VF conversion to monomorphic VT is unclear, 10 
but we hypothesized that catheter ablation of cardiac tissue results in 11 
conduction delay within the Purkinje network to generate new VT circuits. 12 
The aim of this study was to evaluate the prevalence and underlying 13 
mechanism of monomorphic VT after VF ablation, and its outcome over 14 
long-term follow-up.  15 
 16 
Methods 17 
Patients 18 
 Data regarding 21 consecutive patients who underwent catheter 19 
ablation of primary VF due to IHD between December 2003 and May 2014 20 
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were retrospectively analyzed. This study was approved by the Institutional 1 
Review Board of each of the 6 participating hospitals. Twenty of 21 patients 2 
were in electrical storm (more than 3 VF episodes per 24 hours). The 3 
diagnosis of IHD was based on past medical history and clinical findings. 4 
Coronary angiography was performed in all patients. Prior to VF ablation, 5 
various therapies were attempted, including coronary revascularization, heart 6 
failure treatment, antiarrhythmic medications, deep sedation, and overdrive 7 
pacing. However, VF was refractory to those therapies, and an urgent 8 
ablation was then performed. We obtained written informed consent for VF 9 
ablation from each patient and/or their family. Antiarrhythmic drugs were 10 
continued in almost all cases during the ablation.  11 
Mapping and Ablation  12 
 Multielectrode catheters and an ablation catheter were introduced 13 
percutaneously, and a three-dimensional (3-D) mapping system (CARTO, 14 
Biosense Webster, Diamond Bar, CA, USA; or EnSite NavX, St. Jude 15 
Medical, St Paul, MN, USA) was used in all patients. A 3-D voltage map of 16 
the left ventricle was constructed before ablation, and the size of low-voltage 17 
areas was measured. However, this step was completed for only 8 patients, 18 
as the rest of the patients exhibited hemodynamic instability, or an older 19 
version of the 3-D mapping system was used, which lacked the functionality 20 
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to calculate the low-voltage area. We defined regions with an electrogram 1 
voltage <1.5 mV as low-voltage areas. VF was triggered by the same 2 
ventricular premature contraction (VPC) in each patient, and the origin was 3 
identified by determining the earliest activation and/or pace mapping. A 4 
Purkinje potential, a sharp and high-frequency deflection, always preceded 5 
the onset of the trigger VPC, and its localization was carefully mapped. The 6 
earliest Purkinje potential during the trigger VPC was targeted for ablation. 7 
If monomorphic VT was induced and hemodynamically stable, entrainment 8 
and/or activation mapping using the 3-D mapping system were performed to 9 
determine the mechanism and circuit of the VT. Among the induced VTs, 10 
we defined those with the involvement of a bundle branch, fascicle, or distal 11 
Purkinje network in the VT circuit as Purkinje-related VTs,10 and those with 12 
the critical isthmus in the low-voltage area and lacking the involvement of 13 
the Purkinje system as scar-related VTs. Ablation was performed with a 14 
maximum power of up to 50 W and a target temperature of 42°C for the 15 
irrigation catheter, and 58°C for the non-irrigated 4-mm- or 8-mm-tip 16 
catheter. 17 
 The endpoint of the ablation was the elimination of VF and VT. With 18 
the exception of 3 patients with hemodynamic instability (patients no. 2, 17, 19 
and 20), we confirmed the non-inducibility of VF and VT by an 20 
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isoproterenol infusion and electrical stimulation from the right ventricle 1 
and/or left ventricle in all patients at the end of the session.  2 
Follow-up 3 
 The patients were followed-up in the outpatient clinic every 1 to 2 4 
months and/or in the device clinic every 6 months after the ablation; 5 
symptoms, electrocardiograms, and implantable cardioverter defibrillator 6 
(ICD) interrogation logs were checked at every visit. An ICD was implanted 7 
in 17 of 21 patients before or after the ablation. Three patients refused an 8 
ICD, and implantation was avoided in one patient due to their high risk of 9 
skin infection. Clinical success was defined as no recurrence of any 10 
sustained VT or VF during the follow-up period. Fifteen of 21 patients 11 
continued to take class III antiarrhythmic drugs after the ablation. If an 12 
arrhythmia recurred, a change in medication, reprogramming of the ICD 13 
parameters, and re-ablation were considered.  14 
Statistical Analysis 15 
 Categorical variables were expressed as numbers and percentages. 16 
Continuous variables were expressed as the mean ± standard deviation, or 17 
median with 25% to 75% interquartile range (IQR). The variables were 18 
compared using the Student’s t-test or Fisher's exact test. The threshold for 19 
statistical significance was p < 0.05.  20 
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 1 
Results 2 
Patient Characteristics 3 
 Patient characteristics are summarized in Table 1. The mean age was 4 
66 ± 12 years, and 91% of the patients were male. The rates of comorbid 5 
diabetes mellitus, hypertension, and chronic kidney disease were relatively 6 
high: 57%, 67%, and 62%, respectively. Sixteen patients had already 7 
undergone complete revascularization before the occurrence of VF. The 8 
interval from the onset of an infarction to VF occurrence was 1 to 59 days 9 
(median 7 days) in 14 patients with acute or subacute myocardial infarction 10 
(MI), and 1.4 to 20 years (median 9.5 years) in 6 patients with remote MI. 11 
Among 14 patients with acute or subacute MI, 5 had undergone coronary 12 
revascularization after VF events. The other 9 had experienced VF at an 13 
interval of 1 to 8 days (median 3 days) after revascularization. 14 
The patients in this study were divided into two groups: 14 patients 15 
who only had VF before ablation, and 7 patients who had both VF and 16 
concomitant monomorphic VT before ablation. Monomorphic VT was 17 
sustained in all cases. The two groups demonstrated no significant 18 
differences in patient characteristics except for total radiofrequency (RF) 19 
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time. The patients with both VF and monomorphic VT had significantly 1 
longer total RF time.  2 
 VF and/or nonsustained polymorphic VT were repeatedly initiated 3 
by the trigger VPC with the same QRS morphology in all patients. The 4 
morphology of the VPC was a right bundle branch block (RBBB) 5 
configuration with a superior axis in 15 patients, an RBBB configuration 6 
with an inferior axis in 5 patients, and an atypical left bundle branch block 7 
(LBBB) configuration with a superior axis in 1 patient. The mean number of 8 
failed antiarrhythmic drugs was 2.9 ± 1.2, corresponding to 62%, 62%, 95%, 9 
and 19% failed antiarrhythmic drugs with class IB, class II, class III, and 10 
class IV (verapamil), respectively. Nine patients required mechanical 11 
support such as an intraaortic balloon pump (patients no. 9, 12, 13, 15, 16, 12 
17, 19, 20, and 21) and extracorporeal membrane oxygenation (patients no. 13 
13, 15, and 20) to assist their hemodynamic state. 14 
Mapping and Ablation 15 
 The site of the target VPC was located in the left ventricular septum 16 
in 18 patients, and in the anterolateral area in 3 patients, which was within 17 
the border of the low-voltage areas of a prior MI. In all patients, VF was 18 
acutely suppressed, and the electrical storm subsided after RF energy 19 
applications targeting the Purkinje potentials that preceded the onset of the 20 
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trigger VPC. No major complications were associated with the ablation 1 
procedures. 2 
Conversion of VF to New Monomorphic VT 3 
The therapies used in this study cohort are outlined in the flowchart 4 
(Figure 1). Among the 21 patients with primary VF, 14 had only VF before 5 
the ablation. In these 14 patient, the first ablation for VF was performed 6 
successfully, and the non-inducibility of any ventricular arrhythmias was 7 
confirmed by programmed stimulation at the end of the session. After this 8 
first session of ablation, total elimination of VF was achieved during the 9 
follow-up period in 6 of the 14 patients who had only VF (and no 10 
monomorphic VT) before ablation. New occurrence of monomorphic VTs 11 
after the first ablation was seen in 4 patients (29% of patients who had only 12 
VF before ablation), while VF recurred in 4 patients. The interval of time 13 
between the ablation and the occurrence of the new VT ranged from 4 hours 14 
to 29 days (median 4 days) (Table 2). These new monomorphic VTs were 15 
successfully suppressed by a second ablation session in all 4 patients. Two 16 
patients with recurrent VF underwent a second ablation, which achieved 17 
acute suppression of the VF; however, in both of these patients, VF recurred 18 
even after the second ablation session. The other two patients with recurrent 19 
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VF received only medical therapies and did not undergo re-ablation because 1 
the electrical storm subsided. 2 
Concurrence of Monomorphic VT before VF Ablation 3 
Seven patients demonstrated concurrent monomorphic VT before the 4 
ablation (Figure 1). In 2 of them, both VT and VF were successfully 5 
eliminated after the first ablation session. Of the remaining 5 patients, both 6 
VF and VT recurred in 2 patients, and VF alone recurred in 3 patients. Two 7 
patients with VF and VT recurrence, and 1 patient with only VF recurrence 8 
underwent a second ablation, which achieved complete arrhythmia 9 
suppression. The remaining 2 patients with VF recurrence did not undergo 10 
re-ablation and received only medical therapy due to the absence of 11 
electrical storm. 12 
Mechanism of Monomorphic VTs 13 
 Monomorphic VTs were documented in 11 patients: newly emergent 14 
monomorphic VT after the first ablation for VF was noted in 4 patients, and 15 
concomitant monomorphic VTs before the ablation in 7 (Table 3). Three of 16 
4 patients with new monomorphic VTs had Purkinje-related VTs: an 17 
inter-fascicular VT in 1 case (patient no. 3), and Purkinje VTs arising from 18 
the left distal Purkinje network in 2 cases (patients no. 4 and 13). The other 19 
VT (in patient no. 18) was scar-related, and unrelated to the Purkinje system. 20 
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All 7 cases of concomitant monomorphic VT before the ablation were 1 
Purkinje-related VTs. All 10 Purkinje-related VTs (i.e., previously present 2 
and newly developed) represented cases of very fast VT (mean cycle length 3 
[CL], 286 ± 53 ms), and were unmappable due to hemodynamic 4 
compromise; nonetheless, all were successfully ablated, guided by 5 
pace-mapping, at the site where Purkinje potentials were recorded during 6 
sinus rhythm. 7 
 Figure 2 shows an example of the conversion of VF into sustained 8 
monomorphic VT after VF ablation (patient no. 4). During a VF storm, two 9 
types of VPC were present (Figure 2A). Both VPCs had an RBBB 10 
configuration with a superior axis. While VPC2 was always isolated, VPC1 11 
exclusively induced VF or nonsustained polymorphic VT. The ventricular 12 
tachyarrhythmia was always polymorphic VT or VF, and monomorphic VT 13 
was not observed. The trigger VPC1 was successfully eliminated by ablation 14 
at the scar border zone with preceding Purkinje potentials (Figure 2C). One 15 
month after the VF ablation, an ICD intervention for the “VF zone” occurred. 16 
Electrocardiogram monitoring and ICD interrogation revealed that a rapid 17 
sustained monomorphic VT (CL, 240 ms) was initiated by VPC2 and 18 
terminated by the ICD shock (Figure 2B). The QRS configurations of the 19 
monomorphic VT and VPC2 were similar. This rapid monomorphic VT was 20 
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successfully ablated at a single site with a diastolic Purkinje potential during 1 
the VT, and this site was located within the same low-voltage area as the 2 
Purkinje network responsible for the VF that was successfully ablated in the 3 
1st session (Figure 2C). After the ablation, the VT became noninducible, and 4 
VPC2 was also abolished. 5 
 Conversion from VF to Purkinje-related monomorphic VT 6 
sometimes occurred after a very short interval from the VF ablation. Figures 7 
3–5 show an example of the conversion from VF to monomorphic VT 8 
shortly after the VF ablation (patient no. 13). An urgent ablation was 9 
performed for a primary VF storm (Figure 3A); however, it resulted in a 10 
recurrent electrical storm of a newly emergent monomorphic VT 4 hours 11 
after the first ablation session (Figure 3B). On the following day, a second 12 
urgent ablation was performed. The target VPC had an RBBB configuration 13 
with an inferior axis and was similar to the QRS configuration during 14 
monomorphic VT. In the second session, sustained monomorphic VT, not 15 
VF, was repeatedly induced by the VPC. Diastolic Purkinje potentials were 16 
recorded from the left ventricular mid-septum during the VPC that preceded 17 
the onset of the QRS by 150 ms (Figure 4A). The coupling interval from the 18 
prior conducted QRS in sinus rhythm to the trigger Purkinje potential was 19 
320 ms. A diastolic Purkinje potential was also recorded during the 20 
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monomorphic VT. From this site, sustained monomorphic VT was 1 
reproducibly induced by a single stimulus with the same coupling interval 2 
(Figure 4B). Pacing from this site terminated the VT without global capture 3 
(Figure 5). After the RF energy application to this site, which was in the 4 
same low-voltage area as the sites of the first successful ablation, the VT 5 
became noninducible (Figure 6), and the trigger VPC was eliminated. 6 
Long-term Follow-up after Ablation 7 
 Bailout from a VF/VT storm was successfully achieved in one or two 8 
procedures (mean, 1.4 ± 0.5 procedures) in all patients. There were no VF 9 
storms after the ablation during the median follow-up of 28 months (IQR: 10 
16–68 months). Patient no. 2 died from heart failure 1 month after the 11 
procedure and was excluded from the calculation of follow-up periods 12 
because of insufficient follow-up data. 13 
Six patients (29% of the total) experienced arrhythmia recurrences. 14 
In 4 cases (patients no. 12, 15, 16, and 20), one to three episodes of VF 15 
occurred within 5 days after the ablation and resolved spontaneously with 16 
medical therapy alone. In the other 2 patients (patients no. 6 and 14), VF 17 
recurred at 25 and 35 months, respectively. These patients received 18 
additional medical therapies and no subsequent ICD intervention. During the 19 
follow-up period, 10 patients died: 3 from heart failure, 2 from stroke, 2 20 
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from sepsis, 2 from cancer, and 1 from pneumonia. There were no deaths 1 
from arrhythmia. 2 
 3 
Discussion 4 
Previous investigators reported that ablation targeting Purkinje 5 
potentials could suppress VF in ischemic cardiomyopathy.2-9 Compared with 6 
previous studies, the present study has reviewed data regarding more cases 7 
of VF ablation in patients with IHD, and collected over a longer follow-up 8 
period. To our knowledge, no previous study has analyzed the conversion of 9 
VF into monomorphic VT by catheter ablation.  10 
Monomorphic VT including Purkinje Fibers in the Circuit 11 
Three of 4 newly emergent monomorphic VTs seen after VF ablation 12 
were Purkinje-related VTs, as were all 7 concomitant monomorphic VTs 13 
before VF ablation. In all patients, the diagnosis of these Purkinje-related 14 
monomorphic VTs was determined by mid-diastolic Purkinje potentials, not 15 
by entrainment pacing. These monomorphic VTs included the Purkinje 16 
system in part of the circuit and were successfully suppressed by ablation 17 
with guidance of Purkinje potentials during sinus rhythm and pace mapping. 18 
Therefore, they were diagnosed as Purkinje-related VTs.  19 
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This study included a relatively small number of scar-related VTs. 1 
We speculate that there are two possible reasons. First, the majority of 2 
patients had acute or subacute MI, and different arrhythmic substrates might 3 
be involved with remote MI. That is, compared to the scar-related isthmus, 4 
the Purkinje network had greater involvement in the establishment of the VT 5 
circuit. Purkinje fibers are relatively resistant to ischemia.11 Second, 95% of 6 
patients had already taken class III antiarrhythmic drugs before ablation, 7 
which might have suppressed the circuit of the scar-related VT in these 8 
patients. 9 
Focal tachycardia and macroreentry have been reported as 10 
mechanisms of Purkinje-related VT.12,13 Because the Purkinje-related VTs in 11 
this study were very fast (mean CL, 286 ± 53 ms), a detailed 12 
electrophysiological study was difficult to perform. However, we could 13 
detect a reentrant mechanism in some patients (e.g., in patient no. 14). 14 
Bogun et al.13 reported that VTs that included Purkinje fibers as part 15 
of the re-entry circuit in patients with a MI exhibited a narrow QRS 16 
configuration of less than 145 ms. However, the mean QRS duration of the 17 
Purkinje-related VT in this study was wider (184 ± 17 ms). We speculate 18 
that one of the reasons for the wider QRS is the shorter VT-CL observed in 19 
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this study. While the mean VT-CL in the study by Bogun et al. was 402 ± 82 1 
ms, the VT-CL in the present study was 286 ± 53 ms.  2 
Conversion to Monomorphic VT after VF Ablation  3 
In 4 of 14 patients with only VF before ablation, conversion to 4 
Purkinje-related monomorphic VT was observed; monomorphic VT, which 5 
was never observed before the VF ablation in these patients based on their 6 
records from ICD interrogation or stay in the intensive care department, 7 
became dominant after the VF ablation. Tsuchiya et al. reported the case of a 8 
patient who exhibited a transition from idiopathic Purkinje-related 9 
polymorphic VT to monomorphic VT after the administration of class IC 10 
drugs14; however, to the best of our knowledge, the present study is the first 11 
retrospective evaluation of conversion to Purkinje-related monomorphic VT 12 
by ablation of ischemic VF.  13 
Although the hypotheses of mother rotors, multiple wavelets, and 14 
focal sources15-17 have been advocated as mechanisms of VF, there is no 15 
single hypothesis explaining the maintenance of VF. In any case, it is clear 16 
that the Purkinje network is closely related to the trigger and maintenance of 17 
VF.3, 18, 19 As a possible mechanism of VT conversion, we speculate that 18 
creating a unidirectional conduction block or conduction delay within the 19 
Purkinje network by ablation organized the unstable reentry circuit into a 20 
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stable one, which caused a newly emergent monomorphic VT. Hayase et al. 1 
reported that the localization of the VF rotor was consistent with the critical 2 
isthmus of the monomorphic VT.20 The VT and VF originated from nearby 3 
regions, which may have created a condition whereby the ablation easily 4 
modified the arrhythmic substrates. In fact, 3 of 4 patients with new 5 
monomorphic VT in this study had Purkinje-related VTs, and the circuits of 6 
these VTs were located within the same low-voltage area, and likely within 7 
the same Purkinje network, as the circuits responsible for the VF that was 8 
ablated during the 1st session. It is important to recognize the existence of 9 
Purkinje-related VT because the ablation strategy for Purkinje-related VT 10 
might differ from that of scar-related VT. That is, the strategy of ablation for 11 
Purkinje-related VT is simply to identify and ablate the Purkinje potential, 12 
which was often located near the VF ablation site. On the other hand, 13 
electroanatomical mapping of the entire affected region is often required in 14 
the ablation of scar-related VT, and all of the possible critical isthmuses 15 
must be eliminated within the wide scar areas. 16 
Outcome after VF Ablation  17 
The efficacy of VF storm ablation6,21 and urgent ablation for 18 
ventricular arrhythmias during acute heart failure22 has already been reported. 19 
In this study, VF recurrence was present in 6 patients; however, the 20 
R20 
 
electrical storms had subsided and all the recurrent arrhythmias were 1 
controlled by medical therapy alone. The results of our study seem to be 2 
comparable to those of previous reports.5, 6, 21, 22 3 
Study Limitations 4 
This study included a relatively small cohort of patients. It is unclear 5 
whether concomitant monomorphic VT was absent before the VF ablation in 6 
patients without ICDs. However, all patients with VF storms were monitored 7 
in the intensive care unit, and no monomorphic VTs were observed. 8 
Therefore, we believe these 4 patients had newly emergent monomorphic 9 
VTs after the VF ablation. It is noteworthy that there was no VF recurrence 10 
concomitant with the newly emergent monomorphic VT after the VF 11 
ablation. 12 
 13 
Conclusion 14 
 VF ablation in patients with IHD was feasible and effective as a 15 
bailout therapy for electrical storm, and resulted in a good outcome in the 16 
majority of patients. However, over a fifth of patients included in this study, 17 
who did not have monomorphic VT prior to ablation, developed 18 
Purkinje-related monomorphic VT after the VF ablation. These newly 19 
emergent VTs were related to the same Purkinje network that had been 20 
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successfully ablated in the 1st session to resolve VF, and were also 1 
successfully suppressed by ablation of the Purkinje system in the 2nd session. 2 
Although VF ablation in IHD appears to have a high success rate in general, 3 
the possibility of conversion from VF to Purkinje-related monomorphic VT 4 
and the existence of new VT circuits in the same Purkinje network at the 5 
initial VF ablation site should always be kept in mind. 6 
 7 
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Tables  1 
Table 1. Patient Characteristics  2 
  
Overall  
(n = 21) 
 Original VA 
p-value  VF only  
(n = 14)  
VF and VT 
(n = 7) 
Age (years) 66 ± 12  66 ± 14 65 ± 6 0.84 
Male sex 19 (91%)  12 (86%) 7 (100%) 0.43 
Diabetes mellitus 12 (57%)  8 (57%) 4 (57%) 0.68 
Hypertension 14 (67%)  11 (79%) 3 (43%) 0.13 
Chronic kidney disease 13 (62%)  9 (64%) 4 (57%) 0.56 
Left ventricular ejection fraction (%) 36 ± 10  37 ± 10 29 ± 8 0.082 
NYHA class 2.6 ± 1.0  2.6 ± 0.9 2.7 ± 1.1 0.76 
Type of ischemic heart disease      
 acute MI 7  5 2  
 subacute MI 7  4 3  
 remote MI 6  4 2  
 myocardial ischemia (non-MI) 1  1 0  
Coronary status      
 3-VD 12  9 3  
 2-VD 5  3 2  
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 1-VD 4  2 2  
Complete revascularization 16 (76%)  10 (71%) 6 (86%) 0.44 
Failed antiarrhythmic drugs before 
ablation 
2.9 ± 1.2 
 
2.6 ± 1.2 3.3 ± 1.4 0.27 
Electrical storm 20 (95%)  13 (93%) 7 (100%) 0.67 
Electroanatomical map      
 Number of points 257 ± 130  300 ± 121 128 ± 16 0.10 
 Size of low-voltage area (cm2)* 100.9 ± 64.7  104.1 ± 70.9 91.2 ± 62.9 0.83* 
 Size of low-voltage area (%)* 54.2 ± 19.7  54.5 ± 20.5 53.4 ± 25.1 0.95* 
Ablation data      
 No. of RF sites  17.6 ± 13.2  16.9 ± 14.7 19.3 ± 10.0 0.71 
 Total RF time (seconds) 998 ± 568  836 ± 570 1377 ± 368 0.048 
*Data recorded only for 8 patients, due to technical limitations. 1 
MI indicates myocardial infarction; NYHA, New York Heart Association; 2 
RF, radiofrequency; VD, vessel disease; VA, ventricular arrhythmia; VF, 3 
ventricular fibrillation; and VT, ventricular tachycardia. 4 
 5 
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Table 2. Details Regarding the Catheter Ablation Procedure 1 
Patient Original VA 
Electrical 
storm 
Mechanism of 
the original VA 
Conversion from 
VF to SMVT 
Interval from 
VF ablation to 
SMVT 
Number of 
required 
procedures 
ICD 
implantation 
(pre or post 
ablation) 
Patients who had only VF before ablation 
1 VF only Yes Purkinje VF 
  
1 post 
3 VF only Yes Purkinje VF Yes 7 days 2 pre 
4 VF only Yes Purkinje VF Yes 29 days 2 pre 
6 VF only Yes Purkinje VF 
  
1 post 
7 VF only 
 
Purkinje VF 
  
1 none 
9 VF only Yes Purkinje VF 
  
1 post 
11 VF only Yes Purkinje VF 
  
1 post 
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13 VF only Yes Purkinje VF Yes 4 hours 2 post 
14 VF only Yes Purkinje VF 
  
2 pre 
15 VF only Yes Purkinje VF 
  
1 post 
16 VF only Yes Purkinje VF 
  
2 none 
18 VF only Yes Purkinje VF Yes 1 day 2 post 
19 VF only Yes Purkinje VF 
  
1 post 
21 VF only Yes Purkinje VF 
  
1 post 
      
Patients who had both VF and VT before ablation 
2 VF and VT Yes 
Purkinje VF 
Purkinje VT    
1 post 
5 VF and VT Yes 
Purkinje VF 
Purkinje VT    
2 post 
R31 
 
8 VF and VT Yes 
Purkinje VF 
Purkinje VT   
1 post 
10 VF and VT Yes 
Purkinje VF 
Purkinje VT   
2 pre 
12 VF and VT Yes 
Purkinje VF 
Purkinje VT   
1 post 
17 VF and VT Yes 
Purkinje VF 
Purkinje VT   
2 none 
20 VF and VT Yes 
Purkinje VF 
Purkinje VT 
    1 none 
 1 
ICD indicates implantable cardioverter defibrillator; SMVT, sustained monomorphic ventricular tachycardia; 2 
VA, ventricular arrhythmia; VF, ventricular fibrillation; and VT, ventricular tachycardia.  3 
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Table 3. Details Regarding Monomorphic Ventricular Tachycardia 1 
Patient 
VT emergence phase 
(before or after  
VF ablation) 
 VT morphology 
QRS 
duration 
(ms) 
Diagnosis of VT 
VT-CL 
(ms) 
Hemodynamic 
collapse during 
VT 
Patients who had only VF before ablation 
3 After SA + RBBB 210 interfascicular VT 325 Yes 
4 After SA + RBBB 180 Purkinje VT 240 Yes 
13 After IA + RBBB 175 Purkinje VT 280 Yes 
18 After IA + LBBB 160 Scar-related VT 440 No 
       
Patients who had both VF and VT before ablation 
2 Before N/A 165 Purkinje VT 272 Yes 
5 Before SA +  163 Purkinje VT 239 Yes 
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Negative concordance 
8 Before SA + RBBB 195 Purkinje VT 289 No 
10 Before 
SA +  
Negative concordance 
195 Purkinje VT 278 Yes 
12 Before SA + RBBB 170 Purkinje VT 246 Yes 
17 Before IA + RBBB 208 Purkinje VT 419 Yes 
20 Before SA + RBBB 180 Purkinje VT 270 Yes 
 1 
CL indicates cycle length; IA, inferior axis; LBBB, left bundle branch block; N/A, not available; RBBB, right 2 
bundle branch block; SA, superior axis; VF, ventricular fibrillation; and VT, ventricular tachycardia. 3 
 4 
  5 
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Figure legends 1 
Figure 1. Flowchart of arrhythmia management in the study cohort. 2 
Twenty-one patients were referred for VF ablation. Fourteen patients had 3 
only VF, and the other 7 had concomitant monomorphic VT with VF. They 4 
were treated by 1 or 2 ablation procedures. SMVT indicates sustained 5 
monomorphic ventricular tachycardia; VF, ventricular fibrillation; and VT, 6 
ventricular tachycardia. 7 
 8 
Figure 2. Conversion from VF to rapid sustained monomorphic VT after the 9 
VF ablation (patient no. 4).  10 
A, There were two kinds of VPCs. While VPC2 was always isolated, VPC1 11 
exclusively induced VF or nonsustained polymorphic VT. No monomorphic 12 
VT was observed. The trigger VPC1 was successfully eliminated by ablation 13 
at the scar border zone with preceding Purkinje potentials. B, One month 14 
after the VF ablation, monomorphic VT (CL, 240 ms) was initiated by 15 
VPC2 and terminated by the ICD shock. This rapid monomorphic VT was 16 
successfully ablated at the single site with diastolic Purkinje potentials 17 
during VT. After the ablation, the VT became noninducible, and VPC2 was 18 
also abolished. C, Electroanatomical voltage map obtained in the first 19 
session for VF ablation. The red tags indicate the ablation sites for VF. The 20 
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blue tags indicate the Purkinje potentials. The successful ablation site for the 1 
monomorphic VT is superimposed as a white tag positioned at the site of the 2 
Purkinje network, and appears to lie in the same low-voltage area as the 3 
original VF ablation sites. CL indicates cycle length; ICD, implantable 4 
cardioverter defibrillator; VF, ventricular fibrillation; VPC, ventricular 5 
premature contraction; and VT, ventricular tachycardia. 6 
 7 
Figure 3. Conversion from VF to rapid sustained monomorphic VT shortly 8 
after the VF ablation (patient no. 13). 9 
A, Twelve-lead electrocardiogram during the first ablation session. VF was 10 
initiated by the trigger VPC. B, Twelve-lead electrocardiogram during the 11 
second ablation session, which was performed the next day. SMVT (CL, 280 12 
ms) was initiated by the trigger VPC. CL indicates cycle length; SMVT, 13 
sustained monomorphic ventricular tachycardia; VF, ventricular fibrillation; 14 
VPC, ventricular premature contraction; and VT, ventricular tachycardia. 15 
 16 
Figure 4. Successful ablation site of a monomorphic VT (patient no. 13). 17 
 A, On the left ventricular septum, Purkinje potentials (P) were recorded 18 
before the QRS during sinus rhythm and the trigger VPC. While Purkinje 19 
firing with a coupling interval of 320 ms (arrow) conducted to the 20 
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ventricular muscle and produced the VPC, the firing with a shorter coupling 1 
interval (270 ms) did not conduct to the ventricular muscle (arrowhead). A 2 
diastolic Purkinje potential was recorded during VT. B, A single stimulus 3 
(S) from this site with a coupling interval of 320 ms repeatedly induced 4 
sustained monomorphic VT. VPC indicates ventricular premature 5 
contraction; and VT, ventricular tachycardia. 6 
 7 
Figure 5. Termination of the VT without global capture at the successful 8 
ablation site (patient no. 13). 9 
Pacing from the successful ablation site (Figure 4B) could not capture the 10 
ventricle. However, it terminated VT. CL indicates cycle length; and VT, 11 
ventricular tachycardia. 12 
 13 
Figure 6. Electroanatomical mapping (patient no. 13) 14 
This electroanatomical map was created during the 2nd session for VT 15 
ablation. The red tag indicates the ablation site for VF in the 1st session, 16 
superimposed on the same map. The white tag indicates the successful 17 
ablation site for VT in the 2nd session. The brown tags represent additional 18 
ablation sites to prevent the recurrence of ventricular arrhythmias, and the 19 
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blue tags indicate the Purkinje potentials during sinus rhythm. VF indicates 1 
ventricular fibrillation and VT, ventricular tachycardia. 2 










